Attached files
file | filename |
---|---|
EX-32.2 - EX-32.2 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex32d2.htm |
EX-32.1 - EX-32.1 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex32d1.htm |
EX-31.2 - EX-31.2 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex31d2.htm |
EX-31.1 - EX-31.1 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex31d1.htm |
EX-23.1 - EX-23.1 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex23d1.htm |
EX-10.26 - EX-10.26 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex10d26.htm |
EX-4.21 - EX-4.21 - IDERA PHARMACEUTICALS, INC. | idra-20201231xex4d21.htm |
10-K - 10-K - IDERA PHARMACEUTICALS, INC. | idra-20201231x10k.htm |
| Exhibit 10.25 |
|
November 16, 2020
Daniel Soland
[Street Address]
[City, State, Zip Code]
Dear Daniel,
On behalf of Idera Pharmaceuticals, Inc., ("Company"), we are pleased to offer you the position of Senior Vice President & Chief Operating Officer, reporting directly to Vin Milano, President & CEO. This role will report to our Exton Pennsylvania office. Your start date will be determined upon your acceptance of this offer. A summary of the terms of your employment follows.
Exempt Base Salary
Your base salary will be based on a semi-monthly pay schedule at the rate of USD $17,708.34. This annualizes to a full-time equivalent of USD $425,000.16 and will be subject to customary tax withholdings and other payroll deductions. The Company utilizes a semi-monthly pay period, which ends on the 15th and the last day of the month. This position is considered an exempt position for purposes of federal wage-hour law, which means that you will not be eligible for overtime time pay for hours actually worked in excess of 40 in a given work week.
Annual Incentive Plan
Subject to the terms of the Company's Annual Incentive Plan (AIP) then in effect, you are eligible to earn a target incentive award of 40% of your annual base salary. Awards are discretionary and the determination of this discretionary award is subject to evaluation of performance at the corporate and individual levels, and other performance criteria as they apply to your position. AIP will be pro-rated in your first year of hire, based on your start date.
Benefits
You will be eligible to participate in Idera's benefit plans in accordance with the terms and conditions of each plan. Benefits currently include, but are not limited to, medical, dental, vision, life and disability insurance, flexible spending accounts, and a 401(k) savings plan. Full details of these programs, as well as vacation and holidays, will be provided to you under separate cover.
Equity Grant
Upon joining the Company, you will be granted 200,000 options of Idera Common Stock at an exercise price which is equal to the fair market value on the date of hire. This grant is governed by Idera's Stock Incentive Plan and are granted at the discretion of the Compensation Committee of the Board of Directors.
Waiver and Amendment
No amendment to this offer shall be valid unless in writing and signed by you and the Head of Human Resources on behalf of the Company.
Daniel Soland | |
Employment at Will
While we both fully intend to begin our relationship on a positive note, it is essential to understand our employment arrangement. The Company is an “at will” employer, which means that either of us can terminate our employment arrangement at any time and for any reason or no reason.
For purposes of federal immigration law, you will be required to provide the company with documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to the Company within three (3) business days of your date of hire, or our employment relationship with you may be terminated.
Your employment is fully contingent upon a satisfactory background check and your execution and ongoing compliance with the attached Idera Pharmaceuticals’ Non-Disclosure Agreement, Code of Business Conduct and Ethics Agreement and our Insider Trading and Public Disclosure Policies. If the foregoing is satisfactory, please indicate your agreement by signing and returning to us the enclosed copy of this letter, together with a signed copy of the Non-Disclosure Agreement and a signed Acknowledgement and Understanding form of the Code of Business Conduct and Ethics agreement.
Please carefully review the terms and conditions of this offer as outlined in this letter. Feel free to contact Christina Amendola at 484-348-1665 if there is anything further we can do to assist you.
Please confirm your acceptance of this offer by signing the attached copy of this letter; including specifying your actual start date. If we do not receive these executed documents by the end of the business day on 11/17/2020, the offer set forth in this letter shall terminate.
Congratulations Daniel! This position is critical to the continued success and growth of Idera. We are excited to welcome you to Idera and look forward to having you join the team.
Sincerely, | |
| |
/S/ JILL CONWELL | |
Jill Conwell | |
Head of Human Resources | |
Agreed and Accepted, | |
| |
/S/ DANIEL SOLAND | |
Daniel Soland | |
| |
Date: November 16, 2020 | |
| |
Start Date: January 4, 2021 | |